Online Appendix
(Please note that the numbers do not refer to the reference list in the main text, but to the supplement-specific reference
list attached)
References (Please note that this is a separate supplement-specific reference list)
1.
Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, Cayla G, Beygui F, Montalescot G.
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or
proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010;56:134-143.
2.
Jin B, Ni HC, Shen W, Li J, Shi HM, Li Y. Cytochrome P450 2C19 polymorphism is associated with poor
clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep 2011;38:1697-1702.
3.
Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and
cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011;11:199-206.
4.
Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P,
Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD,
Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with
clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304:1821-1830.
5.
Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomas M, Masia R, Marrugat J, Brugada R, Elosua R.
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and
cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012;98:100-108.
6.
Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant
genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ
2011;343:d4588.
7.
Liu YP, Hao PP, Zhang MX, Zhang C, Gao F, Zhang Y, Chen YG. Association of genetic variants in CYP2C19
and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis. Thromb Res 2011;128:593594.
8.
Singh M, Shah T, Adigopula S, Molnar J, Ahmed A, Khosla S, Arora R. CYP2C19*2/ABCB1-C3435T
polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing
helpful? Indian Heart J 2012;64:341-352.
9.
Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Seol SH, Kim DI, Kim BH, Park YH, Je HG,
Jeong YH, Lee SW. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among
coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 2012;110:502-508.
10.
Yamaguchi Y, Abe T, Sato Y, Matsubara Y, Moriki T, Murata M. Effects of VerifyNow P2Y12 test and
CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: A systematic review and meta-analysis.
Platelets 2013;24:352-361.
11.
Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet
function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704-2714.
12.
Mega JL, Thakuria JV, Cannon CP, Sabaline MS. Sequence variations in CYP metabolism genes and
cardiovascular outcomes following treatment with clopidogrel: insights from the CLARITY-TIMI 28 genomic study. In:
J Am Coll Cardiol 2008: Abstract 51, p. A206-A206.
13.
Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP,
Buttner HJ, Neumann FJ. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity
associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or baremetal stents. J Am Coll Cardiol 2008;51:1925-1934.
14.
Malek LA, Kisiel B, Spiewak M, Grabowski M, Filipiak KJ, Kostrzewa G, Huczek Z, Ploski R, Opolski G.
Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with
clopidogrel. Circ J 2008;72:1165-1169.
15.
Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N,
Becquemont L. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. N Engl J Med
2009;360:363-375.
16.
Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon
G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel
after myocardial infarction: a cohort study. Lancet 2009;373:309-317.
17.
Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antoniucci D, Abbate R,
Gensini GF. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary
stent thrombosis. Am J Cardiol 2009;103:806-811.
18.
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W,
Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354362.
19.
Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrler K, Morath T, Schomig A, Kastrati A, von Beckerath
N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary
intervention. Eur Heart J 2009;30:916-922.
20.
Anderson JL. Carriage of the CYP2C19*2 Allele Increases One-Year Risk of Myocardial Infarction Among
Recipients of Drug-Eluting Stents Treated With Clopidogrel. J Am Coll Cardiol 2009;53:A1-A99.
21.
Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US,
Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450
2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-857.
22.
Worral A. The presence of the CYP p450 C19*2 allele is associated with impaired response to clopidogrel as
measured by the verifynow P2Y12 near-patient testing device in patients undergoing coronary angiography. Eur Heart J
2009;30:301-585.
23.
Bhatt DL, Simonsen KL, Eileen S, Mbchb KAAF, Steg PG, Montalescot G, Bhakta N, Hacke W, Flather MD,
Cacoub P, Mark A, Berger PB, Steinhubl SR, Murugesan G, Kottke-marchant K. CHARISMA Genomics. Oral
presentation Transcatheter Cardiovascular Therapeutics 2009.
24.
Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW.
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010;363:1704-1714.
25.
Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schomig A, Kastrati A. Protective effect of the
CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J
2010;160:506-512.
26.
Ko YS, Seung KB, Jang KY, Shin JK, H.S. K, Jeong WS, Kim BJ, Park CS, Park HJ, Choi YS, Park MW.
Association of cytochrome P450 2C19 polymorphism with clinical efficacy of clopidogrel in patients who received
elective percutaneous coronary intervention [Abstr]. Korean Circ J 2010;40 (suppl II).
27.
Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH,
Becker RC. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor
versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-1328.
28.
Malek LA, Przyluski J, Spiewak M, Klopotowski M, Kostrzewa G, Kruk M, Ploski R, Witkowski A, Ruzyllo W.
Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial
infarction. Cardiology 2010;117:81-87.
29.
Sawada T, Shinke T, Shite J, Honjo T, Haraguchi Y, Nishio R, Shinohara M, Toh R, Ishida T, Kawamori H,
Kozuki A, Inoue T, Hariki H, Hirata K. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after
drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 2011;75:99-105.
30.
Yamamoto K, Hokimoto S, Chitose T, Morita K, Ono T, Kaikita K, Tsujita K, Abe T, Deguchi M, Miyagawa H,
Saruwatari J, Sumida H, Sugiyama S, Nakagawa K, Ogawa H. Impact of CYP2C19 polymorphism on residual platelet
reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol 2011;57:194-201.
31.
Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, Ten Cate H, Hackeng CM, Deneer VH,
Ten Berg JM. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel
pretreated patients undergoing coronary stenting. Heart 2011;97:1239-1244.
32.
Komarov A, Shakhmatova O, Donnikov A, Ilyushchenko T, Dzhalilova G, Panchenko E. Carrying of P450
2C19*2 polymorphism and use of proton pump inhibitors increase risk of adverse outcomes after elective PCI in russian
patients with CAD. European Journal of Cardiovascular Prevention & Rehabilitation 2011;18:S100-S125.
33.
Nishio R, Shinke T, Shite J, Sawada T, Toh R, Haraguchi Y, Otake H, Matsumoto D, Kawamori H, Nakagawa
M, Nagoshi R, Kozuki A, Inoue T, Hariki H, Taniguchi Y, Hiranuma N, Hirata K-i. Impact of Cytochrome P450 2C19*2
polymorphism on the target lesion outcome after drug-eluting stent implantation in japansese patients receiving
clopidogrel. Journal of the American College of Cardiology 2011;57:E1299.
34.
Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R,
Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous
coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57:24742483.
35.
Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, Koo BK, Jeong YH, Hwang JY, Kwak CH, Park Y,
Hwang SJ, Ko YG, Shin DJ, Jang Y, Kim HS. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel
response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 2012;98:139-144.
36.
Tang XF, He C, Yuan JQ, Meng XM, Yang YJ, Qin XW, Qiao SB, Liu HB, Wu YJ, Yao M, Chen J, You SJ,
Wu Y, Li JJ, Dai JJ, Chen JL, Gao RL, Chen ZJ. [Impact of cytochrome P450 2C19 polymorphisms on outcome of
cardiovascular events in clopidogrel-treated Chinese pa-tients after percutaneous coronary intervention] [Abstr].
Zhonghua Xin Xue Guan Bing Za Zhi 2011;39:617-620.
37.
Yuan J, Tang XF, Yang YJ, Gao RL. Association between cytochrome P450 2C19 681G>A polymorphisms and
risk of cardiovascular events in coronary heart disease with clopidogrel in Chinese. Eur Heart J 2011;32 (suppl 1):1-312.
38.
Ono T, Kaikita K, Hokimoto S, Iwashita S, Yamamoto K, Miyazaki Y, Horio E, Sato K, Tsujita K, Abe T,
Deguchi M, Tayama S, Sumida H, Sugiyama S, Yamabe H, Nakamura S, Nakagawa K, Ogawa H. Determination of cutoff levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing
elective percutaneous coronary intervention. Thromb Res 2011;128:e130-136.
39.
Harmsze AM, van Werkum JW, Souverein PC, Breet NJ, Bouman HJ, Hackeng CM, Ruven HJ, ten Berg JM,
Klungel OH, de Boer A, Deneer VH. Combined influence of proton-pump inhibitors, calcium-channel blockers and
CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous
coronary intervention. J Thromb Haemost 2011;9:1892-1901.
40.
Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, Hwang SJ, Bliden KP, Kwak CH, Hwang JY, Gurbel
PA. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian
acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011;4:585-594.
41.
Tello-Montoliu A, Jover E, Marin F, Bernal A, Lozano ML, Sanchez-Vega B, Pastor FJ, Hurtado JA, Valdes M,
Vicente V, Rivera J. Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected
population of non ST elevation acute coronary syndrome. Rev Esp Cardiol 2012;65:219-226.
42.
Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schomig A, von Beckerath N,
Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in
clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512-518.
43.
Harmsze AM, van Werkum JW, Ten Berg JM, Zwart B, Bouman HJ, Breet NJ, van 't Hof AW, Ruven HJ,
Hackeng CM, Klungel OH, de Boer A, Deneer VH. CYP2C19*2 and CYP2C9*3 alleles are associated with stent
thrombosis: a case-control study. Eur Heart J 2010;31:3046-3053.
44.
Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schomig A, Kastrati
A. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis
after coronary stenting. Eur Heart J 2011;32:1605-1613.
45.
Bhatt DL, Pare G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N,
Hacke W, Flather MD, Mak KH, Cacoub P, Creager MA, Berger PB, Steinhubl SR, Murugesan G, Mehta SR, KottkeMarchant K, Lincoff AM, Topol EJ, Investigators C. The relationship between CYP2C19 polymorphisms and ischaemic
and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J 2012;33:2143-2150.
46.
Nishio R, Shinke T, Otake H, Sawada T, Haraguchi Y, Shinohara M, Toh R, Ishida T, Nakagawa M, Nagoshi R,
Kozuki A, Inoue T, Hariki H, Osue T, Taniguchi Y, Iwasaki M, Hiranuma N, Konishi A, Kinutani H, Shite J, Hirata K.
Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in japanese
patients receiving clopidogrel. Circ J 2012;76:2348-2355.